About Syrrx
Syrrx is a company based in San Diego (United States) founded in 1999 was acquired by Takeda in February 2005. Syrrx has raised $79 million across 4 funding rounds from investors including Canadian Imperial Bank of Commerce, Takeda Pharmaceuticals and SBIR. Syrrx operates in a competitive market with competitors including Gemseki, SARomics Biostructures, Shamrock Structures, PTM Thera and Crelux, among others.
- Headquarter San Diego, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$79 M (USD)
in 4 rounds
-
Latest Funding Round
$100 K (USD), Grant
Oct 15, 2001
-
Investors
Canadian Imperial Bank of Commerce
& 8 more
-
Employee Count
Not available
-
Acquired by
Takeda
(Feb 05, 2005)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Syrrx
Syrrx has successfully raised a total of $79M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $100 thousand completed in October 2001. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Syrrx
Syrrx has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Canadian Imperial Bank of Commerce, Takeda Pharmaceuticals and SBIR.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Stage-agnostic investments in US life-sciences sectors are managed.
|
Locked | Locked | Locked | |
|
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Syrrx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Syrrx
Investment portfolio details for Syrrx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Syrrx
Detailed financials for Syrrx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Syrrx Comparisons
Peer comparison for Syrrx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Syrrx
Syrrx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Gemseki, SARomics Biostructures, Shamrock Structures, PTM Thera and Crelux, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Delivers advanced solutions for drug discovery and related services.
|
|
| Locked | Locked | Locked |
Services in protein crystallography and structure-based drug design are offered.
|
|
| Locked | Locked | Locked |
Proteomic services like protein cloning, expression, purification and crystallization
|
|
| Locked | Locked | Locked |
Drug development services are provided by PTM Thera.
|
|
| Locked | Locked | Locked |
X-ray crystallography and fragment-based drug discovery services are provided.
|
Detailed competitors of Syrrx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Syrrx
Complete news archive for Syrrx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Syrrx
Syrrx was founded in 1999 and raised its 1st funding round 1 year after it was founded.
Syrrx is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Syrrx is a funded company, having raised a total of $79M across 4 funding rounds to date.
Founded in 1999 and based in San Diego, United States, Syrrx operates in the biotechnology sector. Efforts are directed toward identifying three-dimensional structures of validated drug targets via high-throughput structural biology. Structure-based drug design is applied to develop candidates for metabolic diseases, cancer, and inflammation. A partnership is maintained for commercializing DPP IV inhibitors aimed at type 2 diabetes and related conditions.
Syrrx's top competitors include Shamrock Structures, SARomics Biostructures and Crelux.
Syrrx has 9 investors. Key investors include Canadian Imperial Bank of Commerce, Takeda Pharmaceuticals, SBIR, Lombard Odier, and Bay City Capital.